PDE4-selective inhibitors have been conspicuously tested in a range of pulmonary disorders, including chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis, where much of their clinical efficacy reflects their anti-inflammatory actions [3,4,5,6,7]. This evidence concerns the gene PDE4A and lung disorder.